Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of KPG-818

NCT03949426 is registered in ClinicalTrials.gov with Kangpu Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT03949426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03949426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of KPG-818
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2019
Completion date
September 29, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus